The Chulabhorn Royal Academy held a tribute event honoring Her Royal Highness, the President and Chairperson of the Academy Council, for her exceptional contribution to medical science and her commitment to reducing inequality in cancer treatment access.
Her Royal Highness initiated the establishment of a pharmaceutical production facility at Phimanmas Residence in Chonburi Province, aiming to develop international-standard drug manufacturing processes—from research and development to production and distribution—certified by GMDP PIC/s standards.
The latest achievement is “IMCRANIB 100,” a targeted oral medication that inhibits cancer cell growth and reduces side effects. It is suitable for patients with various types of leukemia and gastrointestinal tumors. This is the first formulation developed and registered in Thailand with the Food and Drug Administration.
Chulabhorn Hospital is piloting the clinical use of the drug with a follow-up system managed by physicians and pharmacists to maximize patient benefits, while also working to expand its accessibility for all approved medical indications.
For more information: Chulabhorn Royal Academy
Link : www.chulabhornchannel.cra.ac.th
EN
CN
DE
JP
TH
